260 related articles for article (PubMed ID: 14624133)
1. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Roberts AW; Thomas A; Rees A; Evans M
Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
[TBL] [Abstract][Full Text] [Related]
3. Vascular effects of TZDs: new implications.
Blaschke F; Spanheimer R; Khan M; Law RE
Vascul Pharmacol; 2006 Jul; 45(1):3-18. PubMed ID: 16740417
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Derosa G; Maffioli P
Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors.
Schernthaner G
Int J Clin Pract; 2009 Jun; 63(6):912-29. PubMed ID: 19490202
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
7. PPARgamma and atherosclerosis.
Staels B
Curr Med Res Opin; 2005; 21 Suppl 1():S13-20. PubMed ID: 15811195
[TBL] [Abstract][Full Text] [Related]
8. PPARgamma agonists and coronary atherosclerosis.
Sulistio MS; Zion A; Thukral N; Chilton R
Curr Atheroscler Rep; 2008 Apr; 10(2):134-41. PubMed ID: 18417068
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
10. The anti-atherogenic effects of thiazolidinediones.
Stojanovska L; Honisett SY; Komesaroff PA
Curr Diabetes Rev; 2007 Feb; 3(1):67-74. PubMed ID: 18220657
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Henry RR
Clin Ther; 2003; 25 Suppl B():B47-63. PubMed ID: 14553866
[TBL] [Abstract][Full Text] [Related]
12. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Simó R; Rodriguez A; Caveda E
Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
[TBL] [Abstract][Full Text] [Related]
13. Vascular effects of PPARgamma activators - from bench to bedside.
Marx N; Walcher D
Prog Lipid Res; 2007 Nov; 46(6):283-96. PubMed ID: 17637478
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X
Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives.
Chiarelli F; Di Marzio D
Vasc Health Risk Manag; 2008; 4(2):297-304. PubMed ID: 18561505
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone: potential beneficial impact on cardiovascular disease.
Viberti GC
Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Stolar MW; Chilton RJ
Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
[TBL] [Abstract][Full Text] [Related]
19. The Clinical Significance of PPAR Gamma Agonism.
Campbell IW
Curr Mol Med; 2005 May; 5(3):349-63. PubMed ID: 15892654
[TBL] [Abstract][Full Text] [Related]
20. Reassessing the cardiovascular risks and benefits of thiazolidinediones.
Zinn A; Felson S; Fisher E; Schwartzbard A
Clin Cardiol; 2008 Sep; 31(9):397-403. PubMed ID: 18781598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
